Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study

A promising CAR T-cell therapy called ARI0002h has shown positive results in patients with heavily treated multiple myeloma. The therapy, developed by academia, was tested in a multicenter study in Spain. At the interim analysis, 80% of patients responded to the treatment within the first 100 days, with 50% achieving complete response. Cytokine-release syndrome was observed in 80% of patients, but no neurotoxic events were reported. The therapy demonstrated low toxicity overall and the potential for point-of-care manufacturing, which could increase its availability worldwide. The study highlights the efficacy and safety of ARI0002h in treating relapsed or refractory multiple myeloma.